世界の腎臓がん治療薬市場 – 業界動向と2030年までの予測

腎臓がん治療薬市場の分析と規模

腎臓がん治療薬市場は、予測期間中に大幅な成長が見込まれています。慢性腎臓病の世界的な発症率の増加と市場の拡大が、この市場拡大の要因となっています。腎臓がんは、世界中の成人の悪性腫瘍全体の約 2.0% を占め、米国ではすべての新規がん症例の 3.8% を占めています。腎臓がん治療薬市場の成長は、腎臓疾患症例の増加と、複数の製薬会社による研究開発活動の増加によって促進されています。

データブリッジ市場調査は、2023年から2030年の予測期間における腎臓がん治療薬市場の成長率を分析しています。腎臓がん治療薬市場の予想CAGRは、上記の予測期間において約5.90％になる傾向があります。市場は2022年に630万米ドルと評価され、2030年までに990万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

腎臓がん治療薬市場の範囲とセグメンテーション

Market Definition

Kidney cancer drugs are a great boon to patients in controlling numerous problems which cause conditions and complications during kidney diseases. It helps treat several symptoms of kidney failure such as loss of appetite, anemia, and feeling out of breath. However, kidney transplantation is considered to be the most standard treatment for advanced kidney disease.  At the advanced stage of kidney cancer, where removal of the cancerous cells is essential, surgical removal of kidney is done to get cure from the disease.

Kidney Cancer Drugs Market Dynamics

Drivers

• Increased Incidence of Kidney Diseases

The increasing incidence of chronic kidney disease globally is majorly responsible for driving the growth of the kidney cancer drugs market. As per the National Kidney Foundation, around 10% of the population is majorly affected by chronic kidney disease (CKD). Renal cell carcinoma accounts for more than 90.0% of all kidney cancers while renal pelvis cancer makes up for <10.0% of microscopically confirmed kidney carcinomas. Clear cell renal cell carcinoma is the most widespread subtype of renal cell carcinoma, affecting around 70.0% of patients with RCC. This demands the increase in kidney cancer drugs.

• Increasing Demand for Immunotherapies

Increasing preference for novel immunotherapies and immune-oncologic agents will push the wide use of targeted therapies to particular patient subpopulations. Programmed death-1 (PD-1) inhibitors are meant to displace TKIs and mTOR inhibitors and work as the primary care in first-and second-line RCC settings. Combination regimens, especially those including PD-1 inhibitors, will be launched in the first-line setting to target major unmet needs, improve progression-free survival, overcome tumor resistance, and maintain the quality of life. Thus, this treatment type is enhancing the market growth.

Opportunities

• Higher Trend of Drug Approvals

The rising approval from the FDA and other authorities for the kidney cancer drugs creates several opportunities for the market growth. For instance, Marck Sharp and Dohme Corp. got approval from Food and Drug Administration (FDA) for KEYTRUDA for the treatment of patients suffering from kidney cancer cell carcinoma. Therefore, all these factors enhance the market expansion.

• Increasing Healthcare Expenditure

The rising expenditure that several organizations are funding lead to the growth of the market. For instance, China offers strong opportunities for market expansion because of the ongoing Healthy China 2020 healthcare reform and the removal of price caps on all medicine categories. The Chinese government has started a supportive 12th Five-Year Plan measures which targets biotechnology as a vital development sector. Moreover, the presence of a large target base with strong unmet clinical needs is expected to boost the market growth.

 Restraints/Challenges

• Side Effects of Kidney cancer Drugs

The major side effects related with these kidney cancer drugs could limit the growth of the kidney cancer drugs market during the forecast period. Effects such as loss of appetite, fever, rashes, can impede the market growth.

• High Cost of Treatment

The huge expenditure associated with these agents hamper the market growth. The generic renal cancer treatments are quite expensive and thus is not affordable to many of the patients. Thus, it hampers the market growth.

This global kidney cancer drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global kidney cancer drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Kidney Cancer Drugs Market            

The COVID-19 pandemic negatively impacted the market due to the reduction in R&D activities for kidney cancer drugs. For instance, per the data published by the National Center for Biotechnology Information in May 2020, the physicians were focused on developing the SARS-CoV-2 vaccine to avoid the rapid spread of the virus globally. Capacity for surgery has also been minimized as theater space and ventilators have been requisitioned to provide extra critical care capacity for COVID-19 patients. Thus, overall, COVID-19 had a major impact on the kidney cancer drugs market.

Recent Developments

• In 2022, Clinical Hospital of the Faculty of Medicine of Ribeirão Preto partnered with Bristol Myers Squibb and São Paulo Research Foundation for the launch of Nivolumab- new drug on renal cancer. Nivolumab is in the Phase 2 clinical trial whose study was initiated in January 18 2022.

Global Kidney Cancer Drugs Market Scope

The kidney cancer drugs market is segmented on the basis of type, drug type, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Renal Cell Carcinoma (RCC)
• Papillary Renal Cell Carcinoma
• Chromophobe Renal Cell Carcinoma
• Unclassified Renal Cell Carcinoma
• Transitional Cell Carcinoma
• Wilms Tumor (Nephroblastoma)
• Renal Sarcoma
• Angiomyolipoma
• Oncocytoma
• Others

Drug Class

• Monoclonal Antibodies
• Trastuzumab
• Pertuzumab
• mTOR Inhibitors
• Sirolimus
• Everolimus
• Temsirolimus
• Immune Checkpoint Inhibitor
• Atezolizumab
• Avelumab
• Durvalumab
• Combined Therapies
• Interleukin-2
• Alpha-Interferon
• Others

Drug Type

• Branded
• Generic

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Kidney Cancer Drugs Market Regional Analysis/Insights

The kidney cancer drugs market is analyzed and market size insights and trends are provided by type, drug type, drug class, distribution channel and end-user as referenced above.

The major countries covered in the kidney cancer drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a highest growth for kidney cancer drugs market throughout the forecasted period due to high smoking, hypertension and diabetic population, and wide presence of major key manufactures of the product.

North America dominates the market due to the wide presence of increased healthcare expenditure and favourable reimbursement policies for the treatment. Furthermore, Europe accounts the second largest market share because of the increased genetic disorders and presence of refined medical facilities.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。   

競争環境と世界の腎臓がん治療薬市場シェア分析

腎臓がん治療薬市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、腎臓がん治療薬市場に関連する会社の焦点にのみ関連しています。

腎臓がん治療薬市場で活動している主要企業は次のとおりです。

• ファイザー社（米国）
• アストラゼネカ（英国）
• ブリストル・マイヤーズスクイブ社（米国）
• ドクター・レディーズ・ラボラトリーズ社（インド）
• エンドインターナショナルplc（アイルランド）
• テバ製薬工業株式会社（イスラエル）
• サン・ファーマシューティカル・インダストリーズ（インド）
• マイランNV（米国）
• ノバルティスAG（スイス）
• ルピナス（インド）
• シプラ社（インド）
• オーロビンドファーマ（インド）
• Fresenius SE & Co. KGaA (ドイツ)
• サノフィ（フランス）
• 武田薬品工業株式会社（日本）
• F. ホフマン・ラ・ロシュ社（スイス）
• アボット（米国）

SKU-57032